LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Home・Aandelen Lijst・Celsion Corp

Celsion Corp

Gesloten

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken
By Trading Economics
Werknemers	25

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+206.91% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-9.9M 938K
Vorige openingsprijs	0
Vorige sluitingsprijs	0

Celsion Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 dec 2025, 23:21 UTC

Winsten

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec 2025, 23:14 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec 2025, 22:01 UTC

Belangrijke Marktbewegers

Costco Wholesale Reports Higher Monthly Sales

3 dec 2025, 21:38 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec 2025, 23:59 UTC

Marktinformatie

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec 2025, 23:13 UTC

Marktinformatie

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec 2025, 23:10 UTC

Winsten

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec 2025, 23:08 UTC

Marktinformatie

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec 2025, 23:06 UTC

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec 2025, 22:45 UTC

Marktinformatie

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec 2025, 22:20 UTC

Winsten

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec 2025, 22:19 UTC

Winsten

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec 2025, 22:17 UTC

Winsten

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec 2025, 22:16 UTC

Winsten

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec 2025, 22:15 UTC

Winsten

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec 2025, 22:10 UTC

Acquisities, Fusies, Overnames

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

3 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 dec 2025, 21:49 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:23 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec 2025, 21:19 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:06 UTC

Winsten

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:04 UTC

Winsten

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec 2025, 21:04 UTC

Winsten

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec 2025, 21:03 UTC

Winsten

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Vergelijking

Prijswijziging

Celsion Corp Prognose

Koersdoel

By TipRanks

206.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 12 USD 206.91%

Hoogste 12 USD

Laagste 12 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celsion Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Celsion Corp - Dist in de afgelopen 3 maanden.

Financieel

Over Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.